Archive | Clinical Trials

Ipilimumab Shows Sustained Efficacy at 7 Years for Stage III Melanoma

Source: OncLive, June 2019 Adjuvant ipilimumab (Yervoy) elicited a 25% reduction in the risk of recurrence or death compared with placebo for patients with surgically resected high-risk, stage III melanoma, according to an updated analysis of findings from the phase III EORTC 18071 study.1 For the analysis, which was conducted after 6.9 years of median […]

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Maximizing BRAF/MEK Inhibition in Melanoma

Source: OncLive, June 2019 Transcript: Hussein A. Tawbi, MD: Starting patients on BRAF and MEK inhibitors does take quite a bit of education for the patient, and I think from my perspective the most important approach is to really inform the patients of what to expect. We spend some time with them going through the timing […]

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Nektar Skin Cancer Combo Spurs More Patient Remissions Over Time

Source: Bloomerg, June 2019 A treatment plan including Nektar Therapeutics’ experimental therapy helped more patients with advanced skin cancer beat back their disease after more than a year of follow up. In updated results from an early-stage study, four additional patients out of 38 were cleared of their cancer after treatment with Nektar’s bempegaldesleukin in […]

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

Source: AP News, June 2019 — ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma — As of the April 5, 2019 data cut-off, five patients treated in the weekly dosing schedule group achieved confirmed responses, one of which was a complete response (CR) — […]

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials